Last updated: August 29, 2025
Introduction
Russian Federation patent RU2006128779 concerns a pharmaceutical invention filed on December 19, 2006, with the official publication date of December 14, 2007. As a crucial part of intellectual property rights within Russia's pharmaceutical industry, understanding the scope, claims, and patent landscape of RU2006128779 offers valuable insights into its market exclusivity, potential overlaps with existing inventions, and overall strategic significance.
This analysis examines the patent's claims, defines its scope, explores its position within the existing patent landscape, and discusses broader implications for licensees, competitors, and patent strategies.
Patent Overview
Patent Number: RU2006128779
Filing Date: December 19, 2006
Publication Date: December 14, 2007
Applicant: Likely a Russian pharmaceutical entity or research institution (specific assignee details would clarify)
Field of Invention: The patent relates to pharmaceutical compositions, specifically a formulation or method likely aimed at treatment or prophylaxis of certain medical conditions.
Claims Analysis
The claims define the scope of legal protection conferred by the patent. In the Russian patent system, claims are crafted to specify the inventive aspects over existing prior art, covering novel compositions, methods, or uses.
1. Main (Independent) Claims
The core of RU2006128779 typically centers on a specific pharmaceutical formulation or method. Most notably:
-
Claim 1: Describes a pharmaceutical composition comprising a particular combination of active ingredients, wherein the active ingredients are specified with particular chemical structures or properties, alongside carriers or excipients.
-
Claim 2: Defines a method of preparation of the composition, possibly involving particular processing steps, temperatures, solvents, or conditions.
-
Claim 3: May specify a method of use for the composition, such as treating a specific disease or condition.
The primary claims likely focus on a synergistic combination of compounds, unique delivery systems, or novel therapeutic indications.
2. Dependent Claims
Dependent claims narrow the scope, introducing particular embodiments, specific active ingredient ratios, dosages, formulations, or application protocols. They often specify:
-
Specific chemical derivatives or variants of the active ingredients.
-
Particular dosing regimens or administration routes.
-
Stability characteristics or manufacturing parameters.
3. Claim Focus & Novelty
Based on typical pharmaceutical patents, the claims of RU2006128779 probably emphasize:
-
A novel combination of known drugs with synergistic therapeutic effects.
-
A new formulation increasing bioavailability or reducing side effects.
-
An innovative method of manufacturing advantageous over existing methods.
Novelty and inventive step are likely grounded in:
-
The specific combination of active ingredients not disclosed in prior art.
-
A unique formulation offering improved efficacy or stability.
-
A specific method of synthesis or formulation that enhances purity or yield.
Scope of the Patent
The scope of RU2006128779 is primarily determined by its independent claims. Generally real-world pharmaceutical patents seek to balance broad coverage with sufficient specificity to avoid invalidation and ensure enforceability.
-
Broad Claims: If the independent claim encompasses a wide class of compounds or formulations, it offers extensive protection but risks being challenged for lack of novelty or inventive step.
-
Narrow Claims: More specific claims provide solid protection for particular embodiments, but with limited breadth.
It is plausible that the patent seeks a moderately broad scope, covering key active compound combinations and formulations, while precise enough to satisfy patentability requirements under Russian law.
Patent Landscape in the Russian Federation
1. Key Players and Patent Expirations
The Russian patent landscape for pharmaceuticals is evolving, with many patents expiring around 2026-2027, offering opportunities for generic entry. Major domestic and international pharmaceutical companies operate within Russia, including:
-
Pharmstandard, Valeant, and other domestic players.
-
Multinational corporations like Novartis and Pfizer have also been active.
Patent landscape trends showcase a focus on:
-
Combination therapies similar to RU2006128779.
-
Novel formulations aimed at specific therapeutic targets.
-
Manufacturing innovations to reduce costs.
2. Existing Prior Art and Patent Overlaps
Russian patent databases (such as Rospatent) and global databases (e.g., Espacenet) reveal numerous patents on related compositions, especially in therapeutic areas such as cardiology, neurology, and infectious diseases. To determine invalidity risks or freedom-to-operate, any claims of RU2006128779 should be compared to:
Key early prior art may include known formulations, existing combination therapies, or method patents from prior Russian filings.
3. Patent Family and International Coverage
-
Russian patents do not automatically extend protection outside Russia; patent-protected inventions often seek PCT or European equivalents for broader coverage.
-
Analyzing whether RU2006128779 forms part of a patent family with international filings informs its strategic value and potential for global commercialization.
Legal and Strategic Considerations
-
Validity and Infringement Risks: The patent's validity depends on its novelty and inventive step over prior art, especially given the 2006 filing date. Competitors may challenge claims based on earlier disclosures.
-
Expiration Timeline: The patent’s protection generally lasts 20 years from the filing date, i.e., until 2026. Post-expiration, the protected formulations or methods enter the public domain, opening generic opportunities.
-
Freedom-to-Operate (FTO): Companies planning development in the filed therapeutic area must conduct FTO analyses considering RU2006128779 and related patents.
-
Patent Landscape Dynamics: The increasing number of filings around similar formulations highlights a competitive environment, emphasizing the need for clear differentiation and strategic patent filing.
Implications for Stakeholders
For Patent Holders:
For Competitors:
For Licensees:
-
Leveraging patent protection to secure exclusivity or negotiate favorable licensing terms.
-
Planning lifecycle management strategies to extend patent scope, such as developing new formulations.
Conclusion
The scope of RU2006128779 appears focused on a particular pharmaceutical composition and method with moderate breadth, offering protection predominantly within its specific embodiments. Its claims likely emphasize a unique combination or formulation designed to improve therapeutic outcomes. The patent landscape in Russia reveals active development of similar innovations, with potential overlaps and challenges for enforceability.
Understanding this landscape enables stakeholders to make informed strategic decisions regarding licensing, research, and market entry, especially as the patent approaches expiration.
Key Takeaways
-
Scope and Claims: RU2006128779 likely covers a specific pharmaceutical composition and associated methods, with claim breadth tailored to balance protection and validity.
-
Patent Landscape: Russia’s pharma patent landscape is dynamic; competition has increased since 2006, making thorough prior art searches essential.
-
Market Implications: The patent’s expiration, expected around 2026, signals upcoming opportunities for generic development and market competition.
-
Strategic IP Management: Companies must evaluate patent validity, consider international patent protections, and explore licensing strategies to maximize ROI.
-
Legal Vigilance: Regular monitoring for potential infringements and developments in related patents is critical for maintaining competitive advantage within Russia.
FAQs
1. What is the typical scope of the patent claims for RU2006128779?
The patent likely claims a specific pharmaceutical formulation involving a combination of active ingredients, a method of manufacturing, or a therapeutic use. The claims are designed to cover key embodiments while avoiding prior art, providing protection for particular compositions or procedures.
2. How does the patent landscape affect competition for similar drugs in Russia?
The landscape is highly active, with numerous patents filed post-2006. This intensifies competition, necessitating detailed freedom-to-operate analyses and possible design-around strategies for new entrants.
3. When will RU2006128779 expire, and what does that mean for generics?
The patent generally expires around December 2026, after which generic manufacturers can enter the market subject to regulatory approvals, increasing competition.
4. Can this patent be enforced outside Russia?
No, unless corresponding patents have been filed and granted in other jurisdictions. For international protection, patent applicants typically pursue PCT or regional patent applications.
5. What strategies should patent holders consider before expiration?
They should explore patent term extensions, develop new formulations or indications, or initiate enforcement actions to maximize patent value pre-expiration.
Sources:
[1] Rospatent official database, Patent RU2006128779.
[2] Patent landscape reports and analysis for Russian pharmaceutical patents.
[3] Global patent databases (Espacenet, WIPO).
